| Recruiting | 2 | 140 | Europe | KEYTRUDA®, Pembrolizumab, MK-3475 | University of Leipzig, University of Göttingen, University of Jena, University of Cologne, University of Ulm, University of Regensburg, Wuerzburg University Hospital, Technical University of Munich, Ernst von Bergmann Hospital, Universitätsmedizin Mannheim, University of Kiel | Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma Stage III, Laryngeal Squamous Cell Carcinoma Stage IV, Squamous Cell Carcinoma of Larynx, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Larynx Stage III, Squamous Cell Carcinoma of the Larynx Stage IV, Laryngeal Squamous Cell Carcinoma, Laryngectomy; Status, Laryngeal Cancer, Laryngeal Neoplasms | 12/28 | 12/30 | | |
NCT05433116: Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC |
|
|
| Recruiting | 2 | 50 | Europe | Pembrolizumab, Keytruda, Lenvatinib, Lenvima | Universität des Saarlandes | Head and Neck Squamous Cell Carcinoma | 09/25 | 09/26 | | |